KYVERNA THERAPEUTICS INC (KYTX) Stock News

USA - NASDAQ:KYTX - US5019761049 - Common Stock

6.76 USD

-0.17 (-2.45%)

Last: 10/14/2025, 8:00:03 PM

6.83 USD

+0.07 (+1.04%)

After Hours: 10/14/2025, 8:00:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KYTX Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill - Mentions: XTLB NERV ADAP GLTO ...

News Image

Top movers in Wednesday's session

13 days ago - By: Bragar Eagel & Squire

KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

21 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

21 days ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

a month ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

a month ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

2 months ago - By: Benzinga

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

2 months ago - By: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Yahoo Finance - Mentions: ALEC

Kyverna Appoints New CFO to Guide Next Growth Phase

3 months ago - By: Kyverna Therapeutics

News Image

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

3 months ago - By: Benzinga - Mentions: CYCC SLP SSII LIXT ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

3 months ago - By: Bragar Eagel & Squire

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

5 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

5 months ago - By: Bragar Eagel & Squire

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

5 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

6 months ago - By: Grabar Law Office - Mentions: MEI MODV MPWR

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your

7 months ago - By: Grabar Law Office - Mentions: HLLY IART VIRT

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

7 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

7 months ago - By: Grabar Law Office - Mentions: AKRO DRVN IART

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is

7 months ago - By: Grabar Law Office - Mentions: DRVN MRCY RKLB

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your

7 months ago - By: Grabar Law Office - Mentions: ADM DRVN MRCY

Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your

7 months ago - By: Grabar Law Office - Mentions: FLNC MRCY SAGE

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

7 months ago - By: Grabar Law Office - Mentions: FLNC MRCY SAGE

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

8 months ago - By: Kyverna Therapeutics

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

8 months ago - By: THE ROSEN LAW FIRM, P. A.

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

8 months ago - By: Faruqi & Faruqi, LLP

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

8 months ago - By: Levi & Korsinsky, LLP

Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX

8 months ago - By: The Gross Law Firm

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX

8 months ago - By: The Law Offices of Frank R. Cruz

Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

8 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX